Kornimate/medical-research-clean huggingface dataset:
the efficacy of implementing a treatment algorithm in managing patent ductus arteriosus (pda) in the extremely low birth weight neonatal population.

Conditions: PDA; Low; Birthweight, Extremely (999 Grams or Less)

Summary: to evaluate whether utilizing a standardized patent ductus arteriosus (pda) treatment algorithm in managing elbw (extremely low birth weight) neonates ≤1000 grams (g) improves clinical outcomes and helps prevent undesirable side effects from pdas.

the treatment of pdas (patent ductus arteriosus) in both the premature and term neonatal population has been the source of thorough research for decades. common treatment pathways include supportive care, pharmaceutical treatment (via indomethacin, ibuprofen, or acetaminophen), and surgical correction. many pdas self-resolve, some are not detected to adulthood, and others may never be discovered. however, determining which neonates with pdas require pharmaceutical versus surgical management, and which can be managed with supportive care, can be difficult to differentiate. a standardized neonatal pda treatment algorithm, one that assesses clinical significance, echocardiogram findings, and systemic pda effects, and one that recommends the optimal treatment course based on these findings, would be helpful in medical management of neonatal pdas in the elbw (extremely low birth weight) population.

Eligibility criteria:
inclusion criteria: * all patients admitted to the bumcp and ccmc nicus with a birth weight ≤1000g and an echocardiogram-confirmed pda, regardless of ga. exclusion criteria: * patients who have serious comorbidities that are not directly related to their symptomatic pda will be excluded (chromosomal abnormalities, serious kidney pathology, other hemodynamically significant heart defects, or serious comorbidities at the researcher's discretion). this will allow the researchers to better determine the efficacy of the treatment algorithm, without the results being confounded by unusual comorbidities.
role of omt in the management of the persistent post-covid-19 symptoms

Conditions: Post-Acute COVID-19 Syndrome

Summary: the goal of this observational study is to determine the feasibility of conducting a large-scale study on the effect of using osteopathic manipulative treatment (omt) to treat patients with post-covid-19 symptoms. the main questions it aims to answer are: 1. is it feasible to conduct a large-scale study of the effect of omt on patients with post-covid-19 symptoms (based on how many patients agree to participate and how many complete the study)? 2. how much change in patients' post-covid-19 symptom severity, quality of life, and ability to return to work can we expect to see following omt? participants will receive omt as directed by their physician and complete questionnaires after every other omt session. 1. participants will complete questionnaires about their post-covid-19 symptoms, quality of life, ability to return to work, and adverse events they experienced 3 days after every other omt session. 2. participants will be sent links to the questionnaires for 4 months or when their symptoms resolve, whichever comes first. 3. additionally, participants will complete a follow-up questionnaire 2 months after they stop receiving omt for their post-covid-19 symptoms or 6 months after enrollment in the study, whichever comes first.


Eligibility criteria:
inclusion criteria: * at least one symptom of post-covid-19 (eg, fatigue, dyspnea, anosmia, arthralgia, headache, sleep disturbances, anxiety/depression, or other problems related to mental health) which was new after diagnosis with covid-19 and has persisted for at least 4 weeks after diagnosis exclusion criteria: * unable to speak, read, and write in english * not mentally competent to give informed consent * inability to complete surveys/questionnaires online

Keywords: osteopathic manipulative treatment long covid post-covid conditions post-acute sequelae of sars-cov-2 infection
pd-1 antibody and lenvatinib plus tace-haic for potential resectable hcc: a single-arm, phase 2 clinical trial

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is one of the most commonly malignant tumors around the world. hepatic resection or liver transplantation is the radical method to cure the disease. however, less than 20% of newly diagnosed patients can undergo radical resection. our latest study showed that 48% potentially resectable hcc received hepatectomy after transarterial chemoembolization plus folfox-based chemotherapy infusion (tace-haic) treatment. recently, several clinical trials (leap-002) showed that pd-1 antibody and lenvatinib had an orr of 36% for advanced patients. the combination of tace-haic with pd-1 antibody and lenvatinib, theoretically can significantly decrease the tumor burden and increase the hepatectomy rate. however, this hasn't been verified in clinical application. to identify a more effective and safety way for treating potentially resectable hcc patients, this study is designed to investigate tace-haic plus pd-1 antibody and lenvatinib will increase the resection rate for those patients.


Eligibility criteria:
inclusion criteria: * diagnosed as potentially resectable with consensus by the panel of liver surgeons * stage bclc a/b/c, without extra-hepatic involvement * no previous anti-hcc treatment * eastern co-operative group performance status 2 or less * liver function: child's a or b (score \< 7) exclusion criteria: * evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy * underlying serve cardiac or renal diseases known or suspected allergy to the investigational agent or any agent given in association with this trial * patients ineligible for hepatic artery embolization, or pd-1 antibody
bevacizumab and endothelium dependent vasodilation

Conditions: Hypertension; Cancer; Endothelial Dysfunction

Summary: the introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. one of the most reported side effects of angiogenesis inhibitors is hypertension. in patients treated with bevacizumab, a monoclonal antibody against vascular endothelial growth factor, hypertension had an overall incidence up to 32%. the increase in blood pressure occurs early in treatment. the etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear. understanding the pathogenesis of this side effect is essential for optimal treatment with this class of drugs. the primary objective is to explore the effect of bevacizumab infusion on endothelium-dependent vasodilation of forearm resistance arteries.


Eligibility criteria:
inclusion criteria: 1. age 18-50 years old 2. male 3. results of serum glucose, lipids and creatinine should be within the laboratory's reference ranges. 4. subject is able and willing to sign the informed consent form prior to screening evaluations. exclusion criteria: 1. documented history of sensitivity/idiosyncrasy to medicinal products or excipients. 2. history of or current abuse of drugs, alcohol or solvents. 3. history of malignant disease. 4. first degree relatives with a history of cancer before the age of 50 5. first degree relatives with a history of premature cardiovascular disease before the age of 50 6. current use of medication. 7. clinical evidence of cardiac or pulmonary disease 8. hypertension ( systole \>140mmhg, diastole \>90mmhg) 9. diabetes mellitus 10. smoking 11. any clinically relevant abnormality on ecg. 12. a history of thrombosis or first degree family members with a history of recurrent thrombosis 13. inability to understand the nature and extent of the trial and the procedures required. 14. previous participation in a study with bevacizumab
study of selinexor (kpt- 330), lenalidomide, & dexamethasone in relapsed/refractory multiple myeloma patients

Conditions: Multiple Myeloma

Summary: this is an open-label, randomized clinical study with two stages to assess the maximum tolerated dose (mtd), efficacy, and safety of selinexor, lenalidomide, and dexamethasone (sld) in patients with relapsed/refractory (rr) multiple myeloma (mm). the stages are dose escalation (phase 1) and expansion (phase 2).

in phase 1 (dose escalation), patients will be randomized to either once-weekly (arm a) or twice- weekly (arm b) dosing with selinexor. dose escalation will be performed within each arm for both lenalidomide and selinexor to determine the selinexor mtd for that arm. each arm will be expanded until approximately 17 patients have been treated at the mtd in each arm. the sponsor and investigator will review the mtd, efficacy, and safety data from phase 1 to determine which dose schedule (arm a or b) to be used as the rp2d dose in the expansion phase. in phase 2 (expansion), patients who had received the mtd dose that was nominated for rp2d will continue at the same dose. patients who did not receive the rp2d for that arm will stay on their phase 1 dose. additional patients will be accrued, as needed, to achieve the target population size of approximately 34 patients at the rp2d.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis, measurable disease and evidence of disease progression of mm. * relapsed or refractory to the most recently received therapy. relapsed is defined as documented evidence of pd after achieving at least sd for ≥ 1 cycle. refractory disease is defined as ≤ 25% response (i.e., patients never achieved minimal response or better) or progression during therapy or within 60 days after completion of therapy. * symptomatic mm, based on imwg guidelines. patients must have measurable disease. exclusion criteria: * smoldering mm. * multiple myeloma that does not express m-protein or flc (i.e., non-secretory mm is excluded), and quantitative immunoglobulin levels cannot be used instead. * polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (poems) syndrome * active mm involving the central nervous system (cns).

Keywords: kpt-330 selinexor multiple myeloma relapsed/refractory lenalidomide dexamethasone karyopharm
observation vs progesterone treatment for management of uterine arteriovenous malformation

Conditions: Arteriovenous Malformations

Summary: a randomized trial which compares conservative management to progesterone based treatment for arteriovenous malformation


Eligibility criteria:
inclusion criteria: * women between age of 18 to 50, diagnosed with avm * hemodynamically stable at clinical presentation exclusion criteria: * unstable patients * contraindication to treatment * us examination not in the us department
effect of neuromuscular reversal with sugammadex on postoperative recovery profile

Conditions: Postoperative Respiratory Condition

Summary: suboptimal reversal of neuromuscular blockage after surgery is possibly related to unfavorable postoperative respiratory conditions and elevated pain levels. rapid and complete reversal of neuromuscular block was not possible untill sugammadex was discovered. the investigators hyposthesise that reversal with sugammadex leads to favorable postoperative respiratory conditions and less pain compared to reversal with neostigmine.


Eligibility criteria:
inclusion criteria: * age 18 years * - bmi \< 35 * -asa class i- iii * -patients scheduled for surgery requiring general anesthesia with the use of nmba's * patients with ability to give oral and written informed consent exclusion criteria: * failure to meet the inclusion criteria * -known or suspected neuromuscular disorders impairing neuromuscular function * -allergies to muscle relaxants, anesthetics or narcotics * a (family) history of malignant hyperthermia * -women who are or may be pregnant or are currently breast feeding * -contraindications for the use of neostigmine * intestinal obstruction, * copd gold 4 * -abnormal heart rhythm (eg. bradycardia: \< 40/min); * -surgery requiring neuraxial anesthesia / analgesia * -preoperative cognitive dysfunction or mental disabilities * -preexistent significant pulmonary disease with preoperative spo2 \< 90% * -preoperative icu treatment / intubation (icu patient); * -need for postoperative icu treatment or ventilation;

Keywords: neuromuscular block neuromuscular reversal postoperative conditions respiratory failure
impact of embryo cryopreservation on birth weight

Conditions: Infertility

Summary: birth weight (bw) is higher after frozen embryo transfer (fet) than after fresh embryo replacement. no study has compared the bw of siblings conceived using the same oocyte/embryo cohort. the aim of this study was to determine whether the freezing-thawing procedure is involved in such difference.


Eligibility criteria:
inclusion criteria: * sibling pairs where fresh embryo replacement resulting in a singleton live birth was followed by transfer of one or two frozen embryos from the same cohort that resulted in a singleton live birth, between may 2007 and june 2015. exclusion criteria: * twin pregnancies and stillbirths were excluded. if the bw of at least one sibling was unknown, the pair was not included in the study.

Keywords: art birthweight siblings cryopreservation epigenetic medical assistance to procreation
a multi-omics study of adenomyosis

Conditions: Adenomyosis; Endometriosis; Ectopic Endometrium; Eutopic Endometrium; Genomics; Transcriptomics; Metabolomics

Summary: this study aims to analyze the multi-omics results between eutopic endometrium, adenomyosis and endometriosis of patients diagnosed of adenomyosis with and without endometriosis. the multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. a comprehensive multi-omics will reveal the pathogenesis of adenomyosis.


Eligibility criteria:
inclusion criteria: * confirmed adenomyosis and/or endometriosis * signed an approved informed consents * feasible for biopsy exclusion criteria: * not meeting all of the inclusion criteria
effects of rlic on motor learning in middle-aged and older adults

Conditions: Adults; Older Adults

Summary: the purpose of this research is to determine if the beneficial effects of remote limb ischemic conditioning on learning seen in young adults are found in middle-aged and older adults.

ischemic conditioning is an endogenous phenomenon in which exposing a target organ or tissue to one or more brief episodes of ischemia results in protection of that organ against subsequent ischemia. the effects of ischemic conditioning are not confined within an organ but can be can be transferred from one organ to another, a technique called remote ischemic conditioning. a clinically feasible method for this is remote limb ischemic conditioning (rlic), where episodes of ischemia and perfusion are induced with a blood pressure cuff placed on the arm. the overall goal of this line of work is to use ischemic conditioning to enhance learning and outcomes in persons with neurologic injuries. two previous studies have shown that remote limb ischemic conditioning (rlic) can enhance learning a motor task in healthy young adults. the next step is to determine which individuals would receive maximum benefit from rlic before applying these findings to clinical rehabilitation populations such as stroke. numerous factors, such as age, body mass index (bmi), sex, and cardiovascular comorbidities may influence the response. the current study determines if rlic can enhance learning in middle-aged and older adults with their burden of co-morbidities.

Eligibility criteria:
inclusion criteria: 1. 40-80 years old 2. had sufficient cognitive skills to provide informed consent and actively participate. exclusion criteria (determined by self-report): 1. history of a neurological condition, balance impairment, or vestibular disorder. 2. history of attentional disorders (add/adhd) that could affect learning. 3. history of sleep apnea which could confound the effects of rlic. 4. presence of lower extremity condition, injury, or surgery that would compromise performance on the balance task. 5. learning disability, sensory, or communication problem that would prevent completion of the study. 6. history of epilepsy, peripheral vascular disease, or blood diathesis which could contraindicate rlic. 7. current intensive weight lifting or interval training exercise which could confound the effects of rlic. 8. current substance abuse or dependence.

Keywords: remote ischemic conditioning, motor learning
the use of hydrogen ion water (shan shang water) in the treatment of allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the goal of this clinical trial is to evaluate whether shan shang water (hydrogen ion water) can help treat allergic rhinitis in adults and affect immune markers. does shan shang water reduce allergic rhinitis symptoms? what changes occur in immune markers when using shan shang water? researchers will compare shan shang water to a placebo (an inactive substance) to see if it effectively treats allergic rhinitis. participants will: take shan shang water or a placebo every day for 24 weeks. visit the clinic every four weeks for checkups and tests. record symptoms in a diary, noting things like sneezing, nasal congestion, and any use of medication.

the goal of this clinical trial is to evaluate whether shan shang water (hydrogen ion water) can help treat allergic rhinitis in adults and affect immune markers. the main questions the study aims to answer are: does shan shang water reduce allergic rhinitis symptoms? what changes occur in immune markers when using shan shang water? researchers will compare shan shang water to a placebo (an inactive substance) to see if it effectively treats allergic rhinitis. participants will: take shan shang water or a placebo every day for 24 weeks. dosage: 660 ml of shan shang water (or placebo) three times a day-morning, noon, and evening. drink 30 minutes before meals or when thirsty. avoid drinking 30 minutes before or after meals and before or after brushing teeth with toothpaste. control group: the control group will drink 1,500-2,000 ml of water daily, following their normal routine. visit schedule: participants will visit the clinic every 4 weeks for checkups and tests. participants will also keep a daily diary to track their symptoms, including sneezing, nasal congestion, runny nose, and any medication use. expected results: symptom improvement: the investigators will assess the reduction in allergic rhinitis symptoms (sneezing, nasal congestion, runny nose, and itching). immune response: the investigators will monitor immune markers like ige levels and eosinophil counts every 3 months. conclusion: this trial will determine if shan shang water can be an effective treatment for allergic rhinitis by reducing symptoms and affecting immune markers. the results will provide valuable insights into its potential use as a non-pharmacological treatment option for allergic rhinitis.

Eligibility criteria:
inclusion criteria: * intermittent or persistent recurrent bouts of sneezing, watery nose, itchy and stuffy nose may be accompanied by eye symptoms including itchy, watery eyes, red and burning eyes, with or without wheezing, coughing, shortness of breath and chest tightness shape. * the symptoms are more severe or severe, and have a significant impact on quality of life. exclusion criteria: * pregnant women and parturients. * patients with liver, kidney and heart disease. * patients with past or current tumors. * specific immunotherapy, biologics, or small molecule drug therapy is planned or initiated.

Keywords: allergic rhinitis hydrogen ion water clinical symptoms immune markers
comparison of methods of lumbar sympathetic ganglion block: distance vs angle

Conditions: Lumbar Sympathetic Ganglion Block Indication: Neuropathic Pain, CRPS, Hyperhydrosis Etc.

Summary: lumbar sympathetic ganglion block is used for several neuropathic pain syndromes. the best method of lumbar sympathetic ganglion block is not established. the investigators would compare two methods of lumbar sympathetic ganglion block. one is modified reid method which's entry point is 7\~7.5cm from midline of spinous process of lumbar spine. the other is angular method which's entry angle is 30 degree from anterior-posterior view of c-arm. comparison modified reid method with angular method would be helpful for finding best method of lumbar sympathetic ganglion block.


Eligibility criteria:
inclusion criteria: 1. adults above age of 20 2. undergoing lumbar sympathetic ganglion block indication exclusion criteria: 1. infection 2. bleeding tendency 3. previous spinal surgery history 4. pregnancy 5. illiteracy
docetaxel vs. docetaxel-gemcitabine in breast cancer

Conditions: Breast Cancer

Summary: randomized,non-blinded,multi-center study in patients with metastatic breast cancer.patients will be treated with docetaxel or docetaxel-gemcitabine. aim of the study is to assess the optimal dosage and safety in this setting.


Eligibility criteria:
inclusion criteria: * histologically verified diagnosis of breast carcinoma, at first diagnosis * restricted previous adjuvant chemotherapy (completed \>6 months prior the study) * measurable and/or non-measurable disease * previous radiotherapy is allowed if:terminated at least 10 days prior the sudy therapy, at least one target lesion for evaluation of tumor response has not been irradiated * performance status 0-2 (who, zubrod) * adequate bone marrow reserve defined * adequate liver / renal functions defined exclusion criteria: * any prior systematic chemotherapy for metastatic breast cancer * expected survival time less than 12 weeks * past or current history of malignant neoplasm other than breast carcinoma * except for cured non-melanoma skin cancer or curatively treated in situ carcinoma of the cervix uteri * known brain metastases/leptomeningeal involvement * active uncontrolled infection * symptomatic peripheral neuropathy \> grade 2 according to nci * patients whose lesions are assessable only by radionuclide scan or patients with sclerotic bone lesions as the only site of disease * concomitant illness that is contraindication to the use of corticosteroids * other concomitant serious illness or medical condition, which may worsen due to the treatment

Keywords: breast cancer
role of the peritoneal microenvironment in the pathogenesis and spread of colorectal carcinomatosis

Conditions: Peritoneal Carcinomatosis

Summary: the goal of this project is to investigate the extent and role of mesothelial - mesenchymal transition (mmt) and cancer associated fibroblasts (cafs) in the pathogenesis of colorectal peritoneal carcinomatosis (pc).


Eligibility criteria:
inclusion criteria: • patients presenting with colorectal peritoneal carcinomatosis exclusion criteria: * pregnancy or breast feeding * psychiatric pathology capable of affecting comprehension and judgment faculty * hipec (hyperthermic intraperitoneal chemotherapy) or pipac (pressurized intraperitoneal aerosol chemotherapy) in the past * abdominal radiation treatment